PT  - JOURNAL ARTICLE
AU  - J Pottecher
AU  - V A H Sato
AU  - Y Plétan
AU  - A Comenducci
AU  - V Desort-Henin
AU  - M Jandrot-Perrus
AU  - S Binay
AU  - A Meilhoc
AU  - G Avenard
TI  - A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).
AID  - 10.1183/13993003.congress-2022.2878
DP  - 2022 Sep 04
TA  - European Respiratory Journal
PG  - 2878
VI  - 60
IP  - suppl 66
4099  - http://erj.ersjournals.com/content/60/suppl_66/2878.short
4100  - http://erj.ersjournals.com/content/60/suppl_66/2878.full
SO  - Eur Respir J2022 Sep 04; 60
AB  - Background: Platelets (plt) may contribute to the inflammatory thrombosis in Cov-ARDS. Glenzocimab a humanized monoclonal antibody fragment against plt glycoprotein VI, inhibiting plt binding to the thrombus does affect physiological hemostasis, is assessed in Stroke (ph.II/II) and thrombotic diseases.Method: GARDEN (NCT04659109) was a randomized, double -blind, multicenter, parallel group, ph.IIb trial. Patients (pts) randomized 1/1 to Glenzocimab (1000 mg/day/3days)-placebo. All had confirmed SARS-CoV2, moderate respiratory clinical signs and a prothrombotic status. Primary endpoint: day 4 severe progression.Results: 60 pts enrolled in Brazil & France, aged median 56yrs; 75% male Caucasians with ≥ 1 comorbidity. All had thromboprophylaxis and steroids. Safety analysis confirmed good tolerance of Glenzocimab. No deaths, serious drug-related adverse event nor major bleeding. 31 SAEs in 15 pts mainly related to Cov-ARDS or infection. No difference for the primary endpoint. Insufficient power, imbalance of risk factors (within Glenzocimab group), or lesser role of GPVI in Cov-ARDS pathophysiology are possible reasons.Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 2878.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).